Sign in
Taking people in SpainPhase 4

Intravenous iron and quality of life in older adults after acute coronary syndrome

Tests intravenous iron in older adults with iron deficiency after acute coronary syndrome.

Key facts

Who runs it
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Where
Badajoz, Barcelona, Granada, León, Madrid, Murcia, Pamplona, Valencia, and Vigo, SpainSee the 9 sites
Registry title
Effect of intravenous iron on quality of life in older adults with acute coronary syndrome: a phase IV clinical study
Status
Recruiting
Phase
Phase 4
People taking part
538 people, planned
Started
27 Feb 2026
Expected to end
28 Jan 2028
Type of study
Interventional
Record updated
3 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 65 or older who had an acute coronary syndrome in the last 15 days and have iron deficiency that has not been treated.

Age
65 years or older
Sex
All sexes can join.
Disease stage
Confirmed acute coronary syndrome within a maximum of 15 days before joining.
Earlier treatment
The iron deficiency must be untreated. People treated with intravenous or oral iron in the year before the event cannot join.
Biomarker or test result
Iron deficiency shown by serum ferritin <100 ng/mL or transferrin saturation (TSAT) <20%, found at hospital admission or within 15 days after the cardiac event.

Main reasons for not taking part

  • Active cancer or ongoing bacteremia
  • Heart failure with LVEF <40%
  • Dialysis, or advanced liver or kidney failure
  • Severe anemia (hemoglobin <10 g/dL)
  • Known hypersensitivity to intravenous iron or its excipients

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients aged 65 years or older
  • Patients with a confirmed diagnosis of acute coronary syndrome (ACS) within a maximum of 15 days prior to inclusion
  • Patients with a confirmed diagnosis of iron deficiency at the time of hospital admission or within 15 days after the cardiac event, untreated, and defined by: - Serum ferritin <100 ng/mL, or - Transferrin saturation (TSAT) <20%, according to the European Society of Cardiology guidelines and the SEC_SEMI consensus
  • Ability to understand the study details and to provide written informed consent prior to any trial-related procedures

Who cannot take part

  • Patients with previously diagnosed iron deficiency, identified and treated with intravenous or oral iron within the year prior to the event
  • Patients with active cancer
  • Patients undergoing dialysis, or with advanced hepatic or renal failure
  • Patients with known hypersensitivity to intravenous iron or to any of the excipients in the product
  • Patients with known severe hypersensitivity to other parenteral iron products
  • Evidence of iron overload or disorders in iron utilization
  • Patients with a prior diagnosis of heart failure (HF) with a left ventricular ejection fraction (LVEF) <40%, or who develop this condition during hospitalization or within 15 days following the acute coronary syndrome (ACS) event will be excluded
  • Patients with severe anemia (hemoglobin <10 g/dL) at the time of the event or within the subsequent 15 days
  • Patients with ongoing bacteremia
  • Patients currently participating in other clinical trials involving investigational medicinal products
  • Patients who, in the opinion of the investigator, should not participate in the study due to difficulties in complying with procedures, restrictions, or requirements
  • Terminally ill patients as determined by the IDC-Pal score (Instrument for Diagnosing Complexity in Palliative Care)

Where in Spain

  • Hospital Universitario de BadajozBadajoz, SpainTaking people
  • Hospital Clinic de BarcelonaBarcelona, SpainTaking people
  • Hospital Universitario Clínico San CecilioGranada, SpainTaking people
  • Hospital Universitario De LeonLeón, SpainTaking people
  • Hospital Clínico San CarlosMadrid, SpainTaking people
  • University Clinical Hospital Virgen De La ArrixacaMurcia, SpainTaking people
  • Hospital Universitario de NavarraPamplona, SpainTaking people
  • Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
  • Hospital Alvaro CunqueiroVigo, SpainTaking people

About the trial

What the trial wants to find out

To determine whether patients aged 65 years or older, diagnosed with iron deficiency after an acute coronary syndrome (ACS), who receive intravenous iron treatment have a better quality of life at 6 and 12 months of follow-up compared to patients who do not receive treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Phase IV, open-label, randomized clinical trial on the effect of intravenous iron on quality of life in elderly patients with Acute Coronary Syndrome.
Plain-language title
Intravenous iron and quality of life in older adults after acute coronary syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
3 December 2025